The amount of maximum potential payments receivable under the collaboration arrangement.

No definition available.

Name:	tbph_CollaborationArrangementMaximumPotentialPaymentsReceivable
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of upfront payments receivable under the collaboration arrangement.

+ References

No definition available.

+ Details

Name:	tbph_CollaborationArrangementUpfrontPaymentsReceivable
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of future development and commercialization milestones under the collaborative arrangements.

+ References

No definition available.

+ Details

Name:	tbph_CollaborativeArrangementFutureDevelopmentAndCommercializationMilestones
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of opt in fee under the collaborative arrangements.

+ References

No definition available.

+ Details

Name:	tbph_CollaborativeArrangementOptInFee
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue earned under collaborative arrangements from upfront payments and contingent payments.

+ References

No definition available.

+ Details

Name:	tbph_CollaborativeArrangementsRevenue
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the percentage of profit or loss sharing arrangement as per collaboration agreement.

+ References

No definition available.

+ Details

Name:	tbph_ProfitLossPercentageAsPerCollaborationAgreement
Namespace Prefix:	tbph_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=tbph_JanssenBiotechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=tbph_Td1473Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue - Janssen Biotech Agreement (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 28, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Collaborative Arrangements and Co-Promote Agreement
Percentage of profit share	33.00%			35.00%
Revenue from collaborative arrangements		$ 5,488	$ 7,493	$ 12,120	$ 12,825
Research and development		62,404	46,399	128,417	100,217
Janssen
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	$ 100,000
Percentage of profit share	67.00%
Maximum potential payments receivable	$ 900,000
Revenue from collaborative arrangements		5,479	7,392	12,101	12,715
Deferred revenue		25,700		25,700
Research and development		$ 9,000	$ 9,000	$ 19,200	$ 17,700
Janssen \| Collaborative Arrangement
Collaborative Arrangements and Co-Promote Agreement
Collaborative arrangement, future development and commercialization milestones	700,000
Janssen \| Collaborative Arrangement \| TD-1473
Collaborative Arrangements and Co-Promote Agreement
Collaborative arrangement, opt in fee	$ 200,000